September 5th 2025
In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.
Can COVID-19 Health Policy Inform How to Address Antimicrobial Resistance?
March 7th 2021While the world’s focus remains on COVID-19, beyond this ongoing crisis lingers another that requires leadership, innovation, and collaboration from policy makers, the health care community, and the private sector.
Watch
Discordant Empirical Antibiotic Therapy for Bloodstream Infections Ups Risk of Mortality
September 21st 2020About 1 in 5 patients with bloodstream infections received discordant empirical antibiotic therapy, increasing their risk of mortality independent of sepsis or septic shock, a new study found.
Read More